An amplified signal imaging software for prognosis of cancer enabling the evaluation of clinical efficiency of personalised cancer treatments to an unprecedented level.

Información del proyecto

iaFRET

Identificador del acuerdo de subvención: 807316

DOI

10.3030/807316

Proyecto cerrado

Fecha de la firma de la CE 13 Febrero 2018

Fecha de inicio 1 Febrero 2018

Fecha de finalización 30 Abril 2018

Financiado con arreglo a

• INDUSTRIAL LEADERSHIP - Leadership in enabling and industrial technologies - Information and Communication Technologies (ICT)

Coste total

€ 71 429,00

Aportación de la UE

€ 50 000,00

Coordinado por

FASTBASE SOLUTIONS SOCIEDAD LIMITADA
Spain

Periodic Reporting for period 1 - iaFRET (An amplified signal imaging software for prognosis of cancer enabling the evaluation of clinicalefficiency of personalised cancer treatments to an unprecedented level.)

Período documentado: 2018-02-01 hasta 2018-04-30

Resumen del contexto y de los objetivos generales del proyecto

Current cancer prognosis technologies are highly inaccurate and treatments do not support patient stratification. This leads to negative outcomes as treatments like chemotherapy are simply set to the highest tolerable dose and administered to patients who may not respond at all (up to 75% of cancer patients do not respond to drugs). Our iaFRET platform can examine how proteins act right down to the molecular scale, including how cancer cells are communicating and engaging with one another. This allows staging and grading of the cancer, and analysis of whether it is the original tumor site or a metastasis. It can also assess whether the cancer cells respond to drugs, and the proportion of cells that are resistant. This will allow treatments to be adjusted based on the patient's cancer, and as a companion to new diagnostics, should dramatically improve the survival rate of patients receiving chemotherapy and other treatments. Our overall objectives with the project are to bring our prognosis platform to the market with a lung cancer testing process first, and then to move on to other cancer types.

Trabajo realizado desde el comienzo del proyecto hasta el final del período abarcado por el informe y los principales resultados hasta la fecha

We assessed and validated our business model through research with internal resources and outreach to major stakeholders in the future of our product. These included clinical research organisations, certification and regulation experts, and a cancer research and treatment institute to host our clinical trial. We assessed the market and forces driving growth in cancer research, concluding that not only is there significant business opportunity for us, but a major opportunity to improve clinical cancer care throughout Europe - this will have critical impacts on future EU health objectives, as Europe, despite having only ~12.5% of the world's population, carries about 25% of the world's cancer burden.

Avances que van más allá del estado de la técnica e impacto potencial esperado (incluida la repercusión socioeconómica y las implicaciones sociales más amplias del proyecto hasta la fecha)

We have observed that our platform is significantly more accurate than existing, competing cancer prognostic systems and technologies. We want to quantify this to a 95-99% reduction in false positives, and to support early identification of non-responders or patients with drug-resistant tumours. This can then let hospitals customise treatment to the patient's condition, and whether their cancer is responding to the treatment. Once we achieve marketing authorisation, we can then use the platform to validate tests for other cancer types, and even other diseases with known biomarkers such as diabetes and Alzheimer's Disease.

iaFRET in use.